Campuses

As France's leading biocluster, Genopole is an incubator for cutting-edge projects in biotechnology. Located in the city of Évry, just south of Paris, Genopole provides a unique environment for scientists and entrepreneurs seeking to advance research and innovation.

Discover >

Advantages

Genopole accompanies researchers, postdocs and start-up entrepreneurs through all the phases of their projects to ensure the best possible conditions for business development.

Discover >

Genopole’s citizens

Every day, at Genopole, researchers, entrepreneurs and students cross paths, share ideas and unite forces in a veritable melting pot for innovation.

Discover >

Highlights

Giving wings to research and empowering employment in our community are cornerstones of Genopole's mission. Catch up on recent scientific advances, the accomplishments of our biotech actors and the events that enliven the biocluster.

Discover >

Innovate with us

Discover >
Highlights

Multiple sclerosis and COVID-19: promising results from AB Science


AB Science is a French biotech headed by Alain Moussy with its scientific committee presided by French Academy of Sciences Member Olivier Hermine. Since this summer, the company has been announcing a series of positive results concerning the efficacy of its product, masitinib, in such pathologies as multiple sclerosis, severe asthma resistant to oral steroids, COVID-19 and amyotrophic lateral sclerosis
AB Science L. Gros AB Science L. Gros

AB Science saw the day in 2001 and now employs more than 100 people at its headquarters in Paris and its R&D sites in Évry-Courcouronnes (Genopole), Magny-les-Hameaux, Marseille and Lyon. The company was publicly listed on Euronext in 2010 (€586 M).

The French biotech is headed by Alain Moussy and its scientific committee presided by French Academy of Sciences Member Olivier Hermine. Since this summer, the company has been announcing a series of positive results concerning the efficacy of its product, masitinib, in such pathologies as multiple sclerosis, severe asthma resistant to oral steroids, COVID-19 and amyotrophic lateral sclerosis. More announcements are to come, notably in the setting of Alzheimer’s disease.

Interview with Laurent Gros

Laurent Gros heads AB Science’s drug discovery program at Genopole. We spoke with him about the highly advanced clinical development of masitinib.

You’ve recently announced extremely promising results for the treatment of the two progressive forms of multiple sclerosis…

Laurent Gros: « No other therapeutic product anywhere in the world has ever provided such results in the two progressive forms of multiple sclerosis (MS). Current treatments concern only 50% of patients, those who have relapsing forms of the disease (see inset below) that respond to modulation of the adaptive immune system. Masitinib, a tyrosine kinase inhibitor currently in phase III trials, is aimed at disease forms that respond to modulation of the innate immune system. In our trial involving 656 patients, we have clinically demonstrated that targeting the innate immune system is effective for slowing progressive forms of MS. Our results were announced a few days ago at the joint ACTRIMS-ECTRIMS meeting. »

Does that mean that we can hope to see a cure for these forms of MS thanks to masitinib?

Laurent Gros: « Thinking that orally-administered masitinib will cure this serious and complex disease is illusory, but already, if it can slow its progression, the benefit for patients will be enormous.  They would benefit from a vastly improved quality of life with less relapses, slowed decline and delayed—even possibly no need for—recourse to a wheelchair. Also, our results show that masitinib is not immunosuppressive and that it causes few adverse effects. It may thus be used as a long-term treatment, an important aspect for patients. We will launch a confirmatory phase III study in 2021. Once patients are recruited, at least three years of clinical study will be necessary. ».

Recent results have indicated an antiviral activity of masitinib against SARS-CoV-2. Could you tell us more about that?

Laurent Gros: « With the urgency of the COVID-19 pandemic, current treatment research strategies are largely based on the repurposing of existing therapeutics. Researchers from the University of Chicago recently screened 1900 known molecules. Masitinib was shown to be the best inhibitor of SARS-CoV-2’s principal protease, which is necessary for its replication (article: Drug repurposing screen identifies masitinib as a 3CLpro inhibitor that blocks replication of SARS-CoV-2 in vitro). Those results were obtained through in vitro modeling and thus in vivo proof of concept will be the next step. The American researchers contacted us to optimize their protocol. We’ve laid the foundation for a potential partnership concerning an antiviral indication for masitinib against COVID-19. The American team is targeting patients in early disease whereas we are in a phase II clinical trial exploring the anti-inflammatory action of masitinib in cases of severe disease caused by a potentially fatal overreaction of the immune system.».

What other paths are being explored?

Laurent Gros: « The research done in American universities also suggest that masitinib is active against other coronaviruses and picornaviruses, which opens a large vista of potential antiviral applications. At an international conference held in early September, we also presented promising results from a phase III trial performed in hundreds of patients with severe asthma. We are furthermore in a phase III trial in Alzheimer’s disease, where mast cell-mediated inflammation appears to play an important role. The objective of that trial is to confirm phase II results suggesting that masitinib’s action on that component has a positive effect on disease course. ».

What is your business model?

Laurent Gros: «Our objective is to pursue our research independently. We keep all rights, which lets us maintain our flexibility, reactivity and creativity. Growth is good, but it needs to occur in a reasonable way.».

  • MULTIPLE SCLEROSIS

    More than 100,000 people in France are afflicted by multiple sclerosis (MS), an autoimmune disease that affects the central nervous system. MS involves a progressive degradation of nerve cells by the patient’s own immune system. It exists in two forms:
    – relapsing-remitting MS (RRMS), characterized by relapses (or “attacks”) of the pathology, followed by remissions;
    – progressive MS, characterized by constant diseases exacerbation with serious, invalidating and irreversible handicapping, much worse than that observed in RRMS.

    Progressive MS is classified as primary or secondary (to RRMS), with further characterization as active or not active.  Progressive MS affects 500,000 people across the globe.

Article posted on 24 September 2020

Share
Highlights

The latest news


traitement des plaies diabétiques issu de peau et d’écailles de poissons

CERITD: Treating deep wounds with fish skin

CERITD and the South Île-de-France Medical Center are testing an innovative, natural fish-skin-based treatment for diabetic foot ulcers.

Discover
SYSFATE

Sysfate Team: A tool to digitize organs

Sysfate at Genoscope has combined image analysis and genomics to create MULTILAYER, a tool to digitize biological tissues and organs.

Discover
muscle fiber

Signs of myopathy detected before muscle formation

An I-Stem team has revealed very early embryonic molecular signs of Duchenne muscular dystrophy occurring upstream of muscle development itself

Discover
Neurons representation - Cells affected by CMT

Gene therapy for Charcot-Marie-Tooth disease makes headway

A gene therapy for Charcot-Marie-Tooth disease has been shown to be efficacious in an animal-model study cosigned by a research team created through Genopole support.

Discover
LAST - Makeup by Global Bioenergies

Global Bioenergies launches its makeup brand

Interview with Marc Delcourt, founder and CEO of Global Bioenergies, launches its makeup brand : LAST

Discover
NEB France celebrate 10 years @ Genopole

New England Biolabs France Celebrates 10 Years!

Its French affiliate arrived at Genopole in 2011 and to mark its 10th anniversary in France, the company invites you to participate in monthly activities to be held throughout 2021.

Discover
Visualization and quantification by MTBench technology of protein-protein interactions observed at Opera Phenix + in a cell line.

Seeing in high resolution at the Structural Biology Platform

With the support of Genopole & the University of Évry and to enrich its technological offer, the Structural Biology Platform has acquired the Opera Phenix Plus high content screening (HCS) system.

Discover
MSCA COFUND 2020 - ApogeeBio Laureate

COFUND-MSCA2020 : ApogeeBio chosen by the EC

Submitted by Genopole and its on-site partners, the ApogeeBio project for research grants has been selected by the European Commission for Marie Skłodowska-Curie Actions co-funding (MSCA-Cofund-2020).

Discover
Genhotel -  fibroblastes, cancer & Polyarthrite

Metabolic reprogramming involved in rheumatoid arthritis and cancer

The researchers from GenHotel (University of Évry-Paris Saclay, Genopole) have shed light on certain aspects common to rheumatoid arthritis and cancer.

Discover
Placton - Tara Oceans

Bioinformatics and Tara Oceans

A team from the Genomics Metabolics Laboratory (Genoscope – CEA/CNRS/University of Évry) has developed a bioinformatics method for environmental genomics analyses able to identify species and associations of species.

Discover
Globules rouges - Avancées scientifiques

CRISPR-Cas9 for blood and metabolic diseases – Integrare

In an article published in Nature Communications, an Integrare team headed by Dr. Mario Amendola has described an innovative genome editing strategy aimed at modifying hematopoietic stem cells.

Discover
Généthon - Genopole's Laboratory

Treating more patients with gene therapies – Généthon

A Genethon team has successfully inhibited immune response to adeno-associated virus vectors, and in so doing, opened potential paths for treating more patients with gene therapies.

Discover
COVID-19 Disease Map

A single interactive map for all that is known on COVID-19

The objective for this latter is to build a sole referential comprising the totality of scientific knowledge on SARS-CoV-2/human-host interactions and thus contribute to the identification of therapeutic possibilities.

Discover
cellular membrane

Mapping membrane nanotubes – Lambe

A team from the Genopole-accredited Laboratory for Analysis and Modeling in Biology and the Environment (Lambe) has developed an experimental technique to study cell membrane nanotubes. These largely unknown structures play an essential role in cellular biomolecule transport.

Discover
Laboratory

Toward the industrialization of gene therapies -Polytheragene

Polytheragene is developing a polymer that will improve upon the current market standards for the production of viral particles for therapeutics. The polymer will be used by Genethon and Yposkesi to enhance the bioproduction of gene therapy vectors.

Discover
Jean Weissenbach

Jean Weissenbach: a portrait

Jean Weissenbach, a pioneer in France for the exploration of the human genome and a scientific icon at Genopole, talks about his career in an interview published 18 March 2020 in CNRS News.

Discover
cellular membrane

A nanopore to identify amino acids – Lambe

A team from the Laboratory for Analysis and Modeling in Biology and the Environment (Lambe – University of Évry/University of Cergy-Pontoise/CNRS) used a natural aerolysin nanopore to successfully identify 13 of the 20 amino acids that make up proteins.

Discover
Genopole - European projects

Green light from Europe for the Genopole-coordinated project GEN.ERA

Le projet européen GEN.ERA*, coordonné par Genopole, est sélectionné par la Commission européenne. Il vise à renforcer par une coopération entre clusters, l’internationalisation d’entreprises du secteur de la génomique au-delà du continent européen.

Discover
actus

New accomplishment in gene therapies

A clinical trial for a gene therapy to treat a severe immunodeficiency has provided highly promising initial results.

Discover
View all >
With the support from